ProteinSimple, Inc.

ProteinSimple, Inc.

ProteinSimple, Inc.

Overview
Date Founded

2003

Headquarters

3001 Orchard Parkway,San Jose, CA 95134

Type of Company

Private

Employees (Worldwide)

251 - 500

Industries

Industrial Machinery & Manufacturing
Biotechnology
Hospitals & Patient Services
Medical Support Services

Company Description

ProteinSimple, Inc. develops and commercializes proprietary systems and consumables for protein analysis. Its products are simple western, simple plex, single cell western, MFI, iCE, alphalmager and flourchem. The company was founded by Linda Cahill, Nancy Allbritton, Christopher Sims, Scott Lockard and Jim Schlater on January 15, 2003 and is headquartered in San Jose, CA.

Contact Data
Trying to get in touch with decision makers at ProteinSimple, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Benefit Plan Administrator

Vice President-Sales

Vice President, Simple Plex

Chief Executive Officer

Executive Chairman

Chief Financial Officer

General Manager

Director

Director

Director

Board of Directors

Director at ProteinSimple, Inc.

Founder at Unchained Labs

Managing Director at Essex Woodlands Management, Inc.

Paths to ProteinSimple, Inc.
Potential Connections via
Relationship Science
You
ProteinSimple, Inc.
Recent Transactions
Details Hidden

Bio-Techne Corp. purchases ProteinSimple, Inc.

Details Hidden

ProteinSimple, Inc. raised money in a private placement transaction

Details Hidden

ProteinSimple, Inc. raised money in a private placement transaction

Transaction Advisors
Legal Advisor

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Investment Advisor

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Escrow Agent

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Legal Advisor

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Legal Advisor

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Legal Advisor

Advised onBio-Techne Corp. purchases ProteinSimple, Inc.

Investors
Details Hidden

POSCO BioVentures focuses exclusively on biotechnology investments. Investments are made across all stages of early company development and in a range of disciplines including therapeutics, diagnostics, platform technologies and non-life sciences companies.Approximately 70% of their investments are made in companies with novel, proprietary bio-molecules. The remaining investments are made in other enabling technologies.POSCO BioVentures invests in companies in different stages of development. Early-stage companies make up about one-third of their investments. Late-stage opportunities make up about one quarter of their investments. This includes investments where an exit strategy is expected as the next round of funding. They also consider mid-stage investments where clear milestones toward an exit are defined.

Details Hidden

The Vertical Group focuses on the medical technology and biotechnology sectors. The Vertical Group's investment activities are not restricted by transaction type or company size. The firm manages private partnerships that participate in early-stage and angel financings, later-stage venture capital financings, buyouts of operating companies involved in a recapitalization or corporate spin-off and investments in public companies of all sizes. Investments range from $500,000 to $10 million in venture capital transactions, to over $25 million buyout or public stock transactions. The Vertical Group's private partnerships have an evergreen structure and over 50% of partnership capital is represented by the firm's four founding General Partners and two Special Limited Partners. Because of their evergreen structure, it is not uncommon for The Vertical Group to maintain investment positions for ten years or longer.

Details Hidden

Latterell Venture Partners (LVP) focuses exclusively on investments in large size markets in start-up healthcare companies in the following areas: biotechnology, pharmaceutical, research instrument, biomaterial, medical device and diagnostic ventures. Initial investments range from $50,000 to $10 million, depending on the stage of development of the company's technology or product. LVP expects to support their portfolio companies through financings in the range of $10 million to $20 million per company. The firm leads or co-leads the majority of their investments and typically takes a seat of their portfolio companies' boards of directors.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ProteinSimple, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ProteinSimple, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ProteinSimple, Inc..